ArticleHematology/oncology clinics of North America2011
Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement.
Article in Hematology/oncology clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Intravenous administration of ex vivo expanded human umbilical cord blood-derived CD34⁺ cells in a preterm hypoxic-ischemic encephalopathy mouse model.Scientific reports · 2026Article
- Andrographolide promotes the ex vivo expansion of CD34+ hematopoietic stem cells derived from human umbilical cord blood.Scientific reports · 2025Article
- Effect of expansion of human umbilical cord blood CD34 + cells on neurotrophic and angiogenic factor expression and function.Cell and tissue research · 2022Article
- Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.The Journal of clinical investigation · 2021Article
- Using mitochondrial activity to select for potent human hematopoietic stem cells.Blood advances · 2021Article
- To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.Frontiers in immunology · 2020Review
- Hematopoietic stem cell-independent hematopoiesis and the origins of innate-like B lymphocytes.Development (Cambridge, England) · 2019Review
- GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Fetal Hematopoietic Stem Cell Transplantation Fails to Fully Regenerate the B-Lymphocyte Compartment.Stem cell reports · 2016Article
- Normal and Neoplastic Stem Cells.Cold Spring Harbor symposia on quantitative biology · 2016Review
- Distinct B-cell lineage commitment distinguishes adult bone marrow hematopoietic stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
Corrections and comments
- Reprint of
Authors and funding
2 authors.
Funding
Abstract
Replacement of disease-causing stem cells with healthy ones has been achieved clinically via hematopoietic cell transplantation (HCT) for the last 40 years, as a treatment modality for a variety of cancers and immunodeficiencies with moderate, but increasing, success. This procedure has traditionally included transplantation of mixed hematopoietic populations that include hematopoietic stem cells (HSC) and other cells, such as T cells. This article explores and delineates the potential expansion of this technique to treat a variety of inherited diseases of immune function, the current barriers in HCT and pure HSC transplantation, and the up-and-coming strategies to combat these obstacles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.